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As with most bioavailable transition metals, iron is essential for many metabolic processes
required by the cell but when left unregulated is implicated as a potent source of reactive
oxygen species. It is uncertain whether the brain’s evident vulnerability to reactive species-
induced oxidative stress is caused by a reduced capability in cellular response or an
increased metabolic activity. Either way, dys-regulated iron levels appear to be involved
in oxidative stress provoked neurodegeneration. As in peripheral iron management,
cells within the central nervous system tightly regulate iron homeostasis via responsive
expression of select proteins required for iron ﬂux, transport and storage. Recently proteins
directly implicated in the most prevalent neurodegenerative diseases, such as amyloid-β
precursor protein, tau, α-synuclein, prion protein and huntingtin, have been connected to
neuronal iron homeostatic control. This suggests that disrupted expression, processing,
or location of these proteins may result in a failure of their cellular iron homeostatic roles
and augment the common underlying susceptibility to neuronal oxidative damage that is
triggered in neurodegenerative disease.
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INTRODUCTION
The comparative ease in transition of valency states, most com-
monly between 2+ and 3+, over other metals makes iron one of
the most useful metals in oxidative biology. In a cellular environ-
ment, over half of all enzymes are metalloproteins, a proportion
of which establish complexes with Fe3+ and/or Fe2+ (Waldron
et al., 2009). Within an aerobic environment iron is continuously
redox cycling between Fe3+ and Fe2+ to produce reactive oxy-
gen species (ROS). When liganded within proteins this cycling is
safely guarded, however, when unprotected the ferrous form is
proliﬁc at producing very reactive and damaging hydroxyl radicals
from O2 and H2O2 via Haber–Weiss and Fenton reactions (Fen-
ton, 1894; Haber andWeiss, 1934). ROS production leads to DNA,
lipid, and protein damage (Crichton and Ward, 2014); intrinsic
factors to the increased oxidative stress and cellular damage in
many neurodegenerative diseases.
IRON WITHIN THE BRAIN
The brain not only requires iron for the usual fundamental
metabolic process such as mitochondrial respiration and DNA
synthesis, it is also essential for neurotransmitter synthesis and
metabolism as well as myelin synthesis (Crichton, 2009). As iron
mismanagement in either direction may severely damage the
cell, homeostatic mechanisms have been evolutionarily incorpo-
rated to maintain optimal cell function (Wang and Pantopoulos,
2011). Unsurprisingly the proteins required to regulate cellular
iron homeostasis in the brain are very similar to those used in
the body’s periphery and rely on the two cytosolic labile iron
pool sensors; iron response protein (IRP) 1 and 2, to bind
to their respective iron regulatory elements in the untranslated
mRNA (UTR) of iron responsive proteins (Muckenthaler et al.,
2008). Binding to IRE’s located in the 5′-UTR prevent transla-
tion whereas IRP binding to 3′-UTR IRE’s protect mRNAs against
nuclease degradation. This canonical cis–trans iron regulatory sys-
tem increases IRP binding to the IRE when iron is required and
allows: increased iron uptake through proteins such as transferrin
receptor 1 (TfR1) and divalent metal ion transporter 1 (DMT1);
impaired iron storage through ferritin (Ft); and reduced export
via ferroportin (Fpn; Muckenthaler et al., 2008). When iron is in
excess, the IRPs are no longer able to bind, allowing Ft and Fpn
mRNA translation and increased mRNA degradation of TfR1 and
DMT1.
Despite these common iron-regulated proteins being expressed
within most cell types of the brain, the population of the cells
present within the brain is diverse and dynamic in their func-
tion and requirement of iron. Therefore, differences in how each
cell type regulates its iron is evident by the expression of pro-
teins required for import, storage, and export of iron in neurons
compared to neuroglia such as oligodendrocytes, astrocytes, and
microglia. Circulatory iron transport in the brain is signiﬁcantly
carried out through association with small molecules such as cit-
rate, ascorbate or ATP, however, the iron carrier transferrin is
still present (Malecki et al., 1999; Ke and Qian, 2007). Despite
this, neurons express TfR abundantly and are likely to acquire
iron through the classical holotransferrin endocytosis followed
by DMT1-mediated entrance of iron into the cytosol (Peliz-
zoni et al., 2012). In contrast, astrocytes and oligodendrocytes
do not express TfR and therefore take up non-transferrin bound
www.frontiersin.org April 2014 | Volume 5 | Article 81 | 1
Wong and Duce Neurodegeneration associated proteins regulate iron
iron (NTBI) either through DMT1 (Lane et al., 2010) or some
alternative routes involving the metal inward transporters; “tran-
sient receptor potential cation channel, subfamily C, member
6” (TRPC6; Mwanjewe and Grover, 2004; Giampa et al., 2007),
“L-type voltage-dependent calcium channels” (L-VDCCs; Gaasch
et al., 2007; Lockman et al., 2012) or “Zrt- and Irt-like proteins”
(Zip8 and Zip14; Pinilla-Tenas et al., 2011; Jenkitkasemwong
et al., 2012). Once inside, iron is mostly stored in Ft; how-
ever, abundance varies age-dependently between cell type with
neurons typically containing the least and microglia containing
the most (Benkovic and Connor, 1993). Iron may alternatively
be stored by neuromelanin in select neuronal types, particu-
larly those known to poorly express Ft such as the melanized
dopaminergic neurons of the basal ganglia (Zecca et al., 2003;
Snyder and Connor, 2009). Excess iron is exported from all cell
types using Fpn, a unique iron efﬂux pore that is abundantly
expressed in neurons, microglia, astrocytes, and oligodendro-
cytes (Song et al., 2010). However, spatiotemporal expression
in neurons is variable (Moos and Rosengren Nielsen, 2006). A
glycophosphatidylinositol-anchored form of ceruloplasmin (CP)
expressed in astrocytes is known to facilitate iron efﬂux through
Fpn (Jeong and David, 2003) and a similar role is proposed for
hephaestin expressed in oligodendrocytes (Schulz et al., 2011)
and amyloid-β precursor protein (APP) in neurons (Duce et al.,
2010).
As well as each cell type’s ability to regulate its own iron con-
tent, a continual homeostatic interplay between neurons and the
neuroglia is apparent as with most protein regulatory pathways.
A good example of this is that despite there being limited pres-
ence of the soluble form of CP in the interstitial ﬂuid (Singh et al.,
2013), non-neuronalCPdepletion causes age-dependent neuronal
iron accumulation and cognitive impairment (Jeong and David,
2003). The full regulatory mechanisms of brain iron homeostasis
has yet to be fully understood and are likely to include a number of
redundant pathways for iron import, storage, and export that can
be implemented in order to protect neurons from iron-induced
oxidative stress.
Iron accumulation is evident in the aging brain from a range
of animals including humans and whilst a heterogeneous distri-
bution of iron is present within the brain, most regions have
a continual increase in iron with lifespan (Aquino et al., 2009;
Bilgic et al., 2012). Despite neuronal and neuroglial accumulation
of iron with age, it has generally been considered not to associate
with severe pathology, indicating that these cells are still capa-
ble of safely liganding the metal and guarding against oxidative
stress-induced cellular damage. Evidence of this is shown with a
correlative increase in the expression of the iron storage complex
proteins Ft and neuromelanin with age (Connor et al., 1990; Zecca
et al., 2001). To wholly understand the iron-induced pathology in
neurodegenerative diseases, continued research is required to bet-
ter understand the full homeostatic pathways for iron regulation
in the brain.
IRON IN NEURODEGENERATIVE DISEASE
Most of the brain’s iron is concentrated in the substantia nigra
pars compacta (SN) and basal ganglia, together reaching com-
parable levels to that observed in the liver; a known peripheral
repository of iron (Grifﬁths and Crossman, 1993; Haacke et al.,
2005). Disrupted iron homeostasis focally in this region of
the brain is evident in rare human disorders generally classed
as “neurodegeneration with brain iron accumulation” (NBIA)
disorders. The phenotypic symptoms of choreoathetosis, dys-
tonia, parkinsonism, spasticity, and rigidity that are present in
all forms of NBIA are predominantly associated with neuronal
iron accumulation within this region of the brain [reviewed
by Rouault (2013)]. The four most frequent subtypes have
gene mutations in either; PANK2 [pantothenate kinase-associated
neurodegeneration (PKAN)], PLA2G6 [PLA2G6-associated neu-
rodegeneration (PLAN)], C19orf12 [mitochondrial-membrane
protein-associated neurodegeneration (MPAN)], or WDR45
[beta-propeller protein-associated neurodegeneration (BPAN)].
A further ﬁve more rare NBIA disorders include Aceruloplas-
minemia (a deﬁciency in CP) and Neuroferritinopathy (a deﬁ-
ciency in Ft), and it is only in these two conditions that
the functional mutation is in a known iron-regulated pro-
tein.
It has become increasingly evident that iron dyshomeostasis
may not be pathologically restricted to NBIA disorders, but also a
common underlying phenotype in more prevalent forms of neu-
rodegenerative disease. The accumulation of iron in excess of
that observed with age within these diseases may induce a vari-
ety of adverse effects, including increased oxidative stress, protein
aggregation,mitochondrial dysfunction, and an imbalance in neu-
rotransmitters; all of which are prevalent with neuropathology
(Duce and Bush, 2010; Crichton and Ward, 2014).
The existence of a deﬁnitive correlation between brain iron
homeostasis and neurotoxicity associated with these more preva-
lent forms of neurodegenerative disease still remains to be seen.
Despite some studies suggesting that iron is non-speciﬁcally co-
precipitated with the aggregated proteins pathologically observed
with Alzheimer’s, Parkinson’s, Huntington’s, and prion diseases
(Altamura and Muckenthaler, 2009), evidence described in this
review provides support that iron has a role in the pathogenesis
of these diseases and that previously known proteins associ-
ated with these disease pathologies are involved in neuronal iron
homeostasis.
PARKINSON’S DISEASE
Parkinson’s disease (PD) is the second most prevalent age-related
neurodegenerative disease affecting 1–2% of the population over
65. It has received the most attention in explaining iron’s contri-
bution to the pathogenesis of neurodegeneration. Patients present
with motor dysfunction broadly arising from a loss of dopamin-
ergic neurons within the pars compacta region of SN, while the
SN reticulate is relatively unaffected. Elevated levels of total iron
and a shift in the equilibrium of iron to the oxidized state within
a region that already has a high level of iron in the brain is con-
sidered to contribute to the oxidative stress-induced neurotoxicity
(Dexter et al., 1991;Halliwell, 1992;Wypijewska et al., 2010). How-
ever, more recently it has been observed that the combination of
iron with dopamine is a greater risk factor than each element on
their own, and that the SN pars compacta has a greater “iron-
dopamine index” than other regions of the brain (Hare et al.,
2014). Altered redox-active labile iron in PD is compounded by a
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loss of the buffering capacity of iron storage proteins; neurome-
lanin (Faucheux et al., 2003) and Ft (Connor et al., 1995) as well
as iron-catalyzed aggregation of α-synuclein to form Lewy bodies
in surviving neurons (Lotharius and Brundin, 2002). Contribut-
ing factors that can explain PD-increased iron accumulation are
the elevated expression of the iron import transporter DMT1
(Salazar et al., 2008) and reduced expression of the iron export
pore protein Fpn (Song et al., 2010) as well as CP ferroxidase
activity (Olivieri et al., 2011; Ayton et al., 2012). In vivo imag-
ing of iron by transcranial sonography (TCS) and T2∗ -weighted
magnetic resonance imaging (MRI) has strengthened the iron
hypothesis of PD by illustrating a strong correlation for SN iron
levels with disease severity and duration (Menke et al., 2009; Ulla
et al., 2013). Typically, intraneuronal iron would be controlled
by IRP1/2 response to the cytosolic labile iron pool. However,
iron accumulation with an iron-regulated protein proﬁle that cor-
relates with decreased iron, infers a breakdown in the neuron’s
iron regulatory system with PD. Support for this theory come
from an inability for IRP to correctly respond in models of PD.
Upregulation of IRP1/2 induces a downregulation in Fpn, thus
exacerbating iron accumulation in a 6-hydroxydopamine model
of PD (Song et al., 2010), but is unable to control Ft mRNA
translation despite the elevated labile iron pool in PD (Hirsch,
2006).
ALZHEIMER’S DISEASE
Accounting for 50–80% of all dementia cases, AD is the most
common neurodegenerative disease of individuals over 65. The
neuropathological hallmarks of AD are an accumulation of extra-
cellular amyloid plaques comprising mainly of amyloid-β (Aβ),
and the presence of intraneuronal neuroﬁbrillary tangles that
are comprised of hyperphosphorylated tau. Aβ is proteolytically
derived fromAPP, a ubiquitously expressed type 1 transmembrane
protein also predominantly expressed on the neuronal surface.
A small number of AD cases who tend to have an earlier onset
of disease are caused by autosomal dominance in familial muta-
tions. These mutations are present within regions of APP or its
γ-secretase cleavage proteins; presenilin 1 and 2, and promote the
amyloidogenic processing of APP to increase Aβ generation. The
trisomy mutation associated with Down’s syndrome also increases
Aβ accumulation leading to early AD pathology and is considered
to be caused by the increased copy number of APP that lies within
chromosome 21.
While strong evidence suggests that Aβ is the principal cause of
neurotoxicity andmay be a signiﬁcant contributor to synaptic dys-
function inAD(Roberts et al., 2012), iron accumulation in affected
brain regions, as reported in both post mortem and MRI studies
(Falangola et al., 2005; Jack et al., 2005; Antharam et al., 2012),may
also be a factor in the increased oxidative stress observed in AD
(Castellani et al., 2007). Hippocampal iron accumulation local-
ized in neuroﬁbrillary tangle-containing neurons and the neuritic
processes surrounding senile plaques inAD (Quintana et al., 2006)
correlateswellwith cognitive decline (Ding et al., 2009).Within the
same regions, proteins regulated by iron are also alteredwhereby Ft
is elevated (Grundke-Iqbal et al., 1990; Morris et al., 1994; Bouras
et al., 1997; LeVine, 1997) and both CP expression and activity
are lowered (Connor et al., 1993; Torsdottir et al., 2010). Despite
these changes, transferrin expression levels are a little less clear
with some evidence of a decrease (Connor et al., 1992) while
later reports showing a localized increase within the frontal lobe
(Loefﬂer et al., 1995). As previously suggested, the transport of
iron by transferrin within the brain is minor and only required
by select cells. This may account for the uncertainty in protein
observations despite weak association with AD risk of the C2 vari-
ant to the Tf gene (Robson et al., 2004; Bertram et al., 2007). A
known partner of Tf called HFE protein is also expressed in glia
and neurons around neuroﬁbrillary tangles and senile plaques
of AD (Connor and Lee, 2006) and over the previous decade
numerous genetic association studies have illustrated HFE gene
mutations increase the risk of AD (Nandar and Connor, 2011).
In particular the mutations H63D and C282Y (Sampietro et al.,
2001; Pulliam et al., 2003; Blazquez et al., 2007) cause periph-
eral iron accumulation in AD and possibly has a link with the
APOE gene. The HFE protein carrying the H63D mutation has
also been shown to upregulate the phosphorylation of tau (Hall
et al., 2010).
HUNTINGTON’S DISEASE
Huntington’s disease (HD) is a progressive neurodegenerative
disorder characterized by motor, psychiatric and cognitive dis-
turbances that progress to dementia (The Huntington’s disease
Collaborative ResearchGroup,1993). Prevalence in Europe,North
America, and Australia is ∼5.70 per 100,000 (Pringsheim et al.,
2012). HD is caused by a dominant CAG expansion in the
exon 1 encoded region of the huntingtin gene resulting in the
expression of polyglutamine-expanded mutant huntingtin pro-
tein (The Huntington’s disease Collaborative Research Group,
1993). Similar to most neurodegenerative diseases and iron accu-
mulative disorders, numerous mechanisms have been implicated
in the pathogenesis of HD including oxidative stress (Browne
and Beal, 1994), energetic dysfunction (Panov et al., 2002; Cui
et al., 2006), transcriptional dysregulation (Nucifora et al., 2001;
Dunah et al., 2002), and defective axonal transport (Trushina
et al., 2004). Iron dysregulation occurs in human HD (Dexter
et al., 1991; Rosas et al., 2012) and brain ﬁeld map MRI values
of gene-positive individuals have suggested that alterations of
brain iron homeostasis occur before the onset of clinical signs
(Rosas et al., 2012). Genetic mouse models of HD have also accu-
rately recapitulated the elevated levels of brain iron (Fox et al.,
2007; Chen et al., 2013). These ﬁndings were interpreted to indi-
cate a compensatory response to iron stress occurring in HD
striatum.
PRION DISEASES
Prion diseases are a group of disorders whereby extreme cellular
destruction leads to vacuolization and spongiosis of large areas of
the brain. Within humans the most common form of prion dis-
ease is Creutzfeldt–Jacob disease (CJD) of which∼80% is sporadic
cases. Despite being comparatively rare considering other forms of
neurodegenerative disease, its high risk of infectivity both within
and between species has prompted intense research into the disor-
der. Prion disease is now known to, at least in part, be caused by the
conversion of the prion protein from its regular form (PrPC) into
more of a β-sheeted isoform termed PrP-scrapie (PrPSc; Prusiner,
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1998; Aguzzi and Falsig, 2012). Little doubt remains that PrPSc is
able to initiate infection when inoculated into a recipient animals
brain (Wang et al., 2010) and that this is done by PrPSc autocat-
alyzing its conversion from PrPC. However, the mechanism by
which PrPSc induces neurotoxicity remains to be fully elucidated
as PrPSc levels poorly correlate with disease progression (Caughey
and Baron, 2006).
Accumulation of redox-active iron, partly co-aggregated with
Ft and in association with PrPSc plaques, has been reported in CJD
brains (Petersen et al., 2005; Singh et al., 2009a, 2012). However, it
appears that the increase in total iron may be biologically unavail-
able as the IRP response in the disease indicates iron deﬁciency.
An increase in both Tf and its receptor as well as transcriptional
changes with Ft and IRP1/2 are reported with Tf increase corre-
lating with PrPSc levels (Kim et al., 2007; Singh et al., 2009a). In
reﬂection to the prion diseased brain, cerebrospinal ﬂuid (CSF)
has decreased levels of Tf and increased total ferroxidase activity
(Singh et al., 2011; Haldar et al., 2013). When used in combination
these CSF markers of disease have an accuracy of 88.9% in detect-
ing CJD over other forms of neurodegenerative disease (Haldar
et al., 2013).
THE ROLE OF PATHOLOGICAL PROTEINS IN IRON
As mentioned previously, a number of key iron homeostatic pro-
teins such as CP and Ft, have been known for some time to cause
NBIA disorders as well as be implicated in the more prevalent
neurodegenerative diseases. However, recently a number of key
proteins traditionally associated with the pathogenesis of the neu-
rodegenerative diseases described above have also been implicated
in an iron regulatory role in neurons. This has strengthened the
argument that redox-active iron is a major facilitator of neurotox-
icity in these diseases. Correlative studies on iron accumulation
and altered pathology also support the theory that changes in
iron homeostasis may be a feature in the early progress of the
disease.
AMYLOID-β PRECURSOR PROTEIN
As the name infers APP is the precursor of Aβ; the prevalent pep-
tide found in senile plaques froma range of amyloidogenic diseases
including AD. Proteolytic processing of APP from the neuron is
predominantly through cell surface α-secretase cleavage followed
by cleavagewith the γ-secretase complex. This non-amyloidogenic
processing of APP excludes Aβ production due to the α-secretase
cleavage site residing within the Aβ peptide sequence. The alter-
native processing of APP through the amyloidogenic pathway
requires β-secretase instead of α-secretase to produce Aβ as one
of its products. The amyloidogenic processing of APP requires
the protein to be endocytosed to allow optimal pH conditions for
β-secretase cleavage. As yet it is not functionally clear as to why
two intricate proteolytic pathways are required to cleaveAPP,how-
ever, the altered cellular location and function of cleaved products
could be a likely reason.
Despite a reduced afﬁnity compared to other transitional met-
als, iron binds Aβ and induces Aβ aggregation (Huang et al.,
2004; Ha et al., 2007; Bousejra-ElGarah et al., 2011). This iron
interaction is via His6, His13, and His14 of Aβ and is thought
to be facilitated in a more reduced environment such as the
brain due to the prevalence for the Fe2+ form of iron to bind
Aβ (Bousejra-ElGarah et al., 2011). ROS generated through iron
aggregated Aβ is toxic to neurons (Liu et al., 2011) and may
partly contribute to the neurotoxicity present within the iron
enriched environment around senile plaques (Meadowcroft et al.,
2009; Gallagher et al., 2012). Evidence also supports the same
histidine residues in Aβ binding to the iron center as well as
porphyrin ring of heme (Atamna et al., 2009; Yuan and Gao,
2013). While the interaction with heme reduces Aβ aggregation
(Zhao et al., 2013) it is unclear whether oligomeric Aβ, now
considered to be the neurotoxic species within AD, are prefer-
entially formed instead (Thiabaud et al., 2013). Heme binding
to Aβ also restricts the bioavailability of regulatory heme and
the complex formed has been shown to have peroxidase activity
(Atamna and Boyle, 2006).
Translational regulation of APP through an IRE within the
5′UTR implies an interaction with iron status whereby increased
cytosolic free iron levels translationally upregulate APP expres-
sion (Rogers et al., 2002). APP has recently been identiﬁed as a
facilitator of neuronal iron efﬂux through an interaction with
Fpn (Duce et al., 2010). While some controversy surrounds the
exact mechanism of how APP is involved in the release of iron
from the cell (Ebrahimi et al., 2012; Honarmand Ebrahimi et al.,
2013), APP within a neuronal environment still appears to be
essential to efﬂux iron (Duce et al., 2010; Wan et al., 2012). Deple-
tion on APP in both cultured neurons and mouse models leads
to intracellular iron retention that can be rescued upon the
addition of APP to the extracellular environment (Duce et al.,
2010) or by overexpression of cellular APP (Wan et al., 2012).
Of signiﬁcance, children suffering from Down’s syndrome that
have an increased expression of APP have a reported high risk
of iron deﬁciency and anemia (Dixon et al., 2010; Tenenbaum
et al., 2011), however, further investigation is required to con-
ﬁrm whether this is due to an increase in APP facilitated iron
efﬂux. As with Fpn, it appears that the surface presence of APP
is essential for its role in iron efﬂux. When APP trafﬁcking to the
cell surface is impaired (Lei et al., 2012) or altered by processing
through the amyloidogenic pathway, as with the AD-associated
familial mutation in APP, iron accumulation arises (Wan et al.,
2011).
TAU
Hyperphosphorylated tau has mostly been recognized as the
principal component of neuroﬁbrillary tangles, a pathological
hallmark in a number of neurodegenerative disorders including
AD. Various repeat motifs on tau are known to bind iron in a pH-
and stoichiometric-dependent manner that results in the promo-
tion of phosphorylation and aggregation of the protein (Ma et al.,
2006; Malm et al., 2007; Zhou et al., 2007). While the afﬁnity for
iron within a physiological environment has yet to be established
for tau, binding of Fe2+ appears to preferentially induce phospho-
rylation of tau (Lovell et al., 2004; Chan and Shea, 2006) despite
Fe3+ being the favored state in causing aggregation of tau once it
has been hyperphosphorylated (Yamamoto et al., 2002; Amit et al.,
2008).
Recently, it has been identiﬁed that tau may be required in the
iron-modulatory role of APP (Lei et al., 2012).Mice deﬁcient in tau
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have neuronal iron accumulation that can be reduced in primary
cultures by the extracellular addition of APP or moderate chela-
tors such as clioquinol (Lei et al., 2012). Tau has been implicated
in axonal trafﬁcking of proteins including APP (Islam and Levy,
1997) and it is proposed that impaired trafﬁcking of APP to the
cell surface in tau−/− neurons restricts APP’s ability to facilitate
iron efﬂux through Fpn leading to intracellular iron accumulation
(Lei et al., 2012).
α-SYNUCLEIN
Variance in α-synuclein is sufﬁcient to cause PD in humans
and animal models suggesting a central role in PD pathogene-
sis (Hardy, 2010). This is apparent through several observations;
the overexpression of wild-type α-synuclein through gene dupli-
cation is sufﬁcient to cause parkinsonian symptoms (Singleton
et al., 2003; Chartier-Harlin et al., 2004; Fuchs et al., 2007); the
majority of familial cases of PD are associated with mutations
in α- synuclein (Polymeropoulos et al., 1997; Kruger et al., 1998;
Zarranz et al., 2004; Hardy, 2010); and aggregated α-synuclein is
a core protein found in Lewy bodies. It has been proposed that
this ubiquitously expressed protein is involved in synaptic vesi-
cle formation however, it is currently not understood why the
dopaminergic neurons of the SN that are targeted in PD are
more susceptible to α-synuclein aggregation and toxicity. One
theory as to the vulnerability of the SN is the high levels of
iron within the region that can augment α-synuclein aggrega-
tion. Iron has been shown to bind to the C-terminal region of
α-synuclein and under oxidizing conditions, such as that provided
in dopamine’s presence, denatures the protein and promotes fur-
ther aggregation (Cappai et al., 2005; Binolﬁ et al., 2006; Bharathi
et al., 2007). Redox-active iron is detected in association with α-
synuclein aggregates in Lewy bodies (Castellani et al., 2000), a
phenotype that is likely to cyclically promote iron-mediated oxi-
dation and exacerbate the aggregation of α-synuclein as well as the
other proteins co-aggregated within the Lewy body (Giasson et al.,
2000).
As with APP a strong indication of the importance of
α-synuclein in the regulation of neuronal iron was through the
identiﬁcation of an iron-response element in its 5′UTR that is
required to increase translation when intraneuronal iron is high
(Friedlich et al., 2007; Febbraro et al., 2012). In support of an iron-
associated role of α-synuclein, it has recently been identiﬁed to
modulate cellular iron homeostasis through its ability to reduce
Fe3+ into the biologically active Fe2+ form (Davies et al., 2011).
In accordance with its ferrireductase activity, α-synuclein has a
greater afﬁnity for Fe3+ (Rouault and Tong, 2005) and within a
normal physiological environment such as the SN may provide a
consistent supply of Fe2+ for neuronal metabolic processes such
as enzymatic synthesis of neurotransmitters.
PRION PROTEIN
As well as the signiﬁcant role iron has in prion disease patho-
genesis through PrPSc – Ft generated ROS that was described
above, recent reports have also suggested that PrPC has a nor-
mal physiological role in iron uptake. Cell surface presentation
of PrPC is required for this function and it appears the cop-
per binding octapeptide repeat region of the protein may have
ferrireductase activity (Singh et al., 2013).When the non-modiﬁed
form of PrPC is overexpressed in cultured cells, iron uptake,
and storage is increased (Singh et al., 2009c, 2013) and simi-
larly when expression is depleted by gene knockout in mouse
models, tissue iron deﬁciency correlates with changes to pro-
teins responsive to iron (Singh et al., 2009b). Intriguingly, a
familial mutation in PrPC (P102L) classically associated with
the prion disorder called Gerstmann–Sträussler–Scheinker (GSS)
disease is shown to increase ferrireductase activity and increase
levels of intracellular labile iron (Singh et al., 2013). Accumu-
lating evidence now suggests that PrPC may have a role in the
transferrin and NTBI import into the cell similar to DMT1 or
Zip14. Of note, PrPC bears a phylogenetic relationship to the
ZIP family (Schmitt-Ulms et al., 2009) and has recently been
implicated in neuronal zinc import when complexed to NMDA
receptors (Watt et al., 2012). Similar to the recent identiﬁcation
that Zip14 is able to transport iron as well as zinc, it is worth
noting that the NMDA- PrPC complex involved in zinc import
may also be implicated in neuronal iron import under certain
conditions.
HUNTINGTIN
Mutant huntingtin protein aggregates to form inclusion bod-
ies that represent a pathological hallmark of HD. As with most
aggregated protein structures formed in neurodegenerative dis-
ease, these bodies bind iron and act as centers of oxidative stress
with large amounts of oxidized protein present (Firdaus et al.,
2006). Genetic mouse models of HD that transgenically overex-
press mutant huntingtin accurately recapitulate the elevated levels
of brain iron in the disease (Fox et al., 2007; Chen et al., 2013) and
huntingtin knockdown in zebra ﬁsh models result in an iron deﬁ-
ciency phenotype (Hilditch-Maguire et al., 2000; Lumsden et al.,
2007; Henshall et al., 2009). This suggests that huntingtin is not
only regulated by iron but also involved in iron homeostasis. How-
ever, iron does not interact directly with N-terminal huntingtin
fragments (Fox et al., 2007; Chen et al., 2013) indicating that the
effect of huntingtin on iron may mediate downstream inﬂuences
on iron homeostatic pathways.
CONCLUSION; BRAIN IRON DYSHOMEOSTASIS AS A
THERAPEUTIC TARGET
With increasing evidence indicating that iron dyshomeostasis may
be a mechanism of exacerbating disease pathology in these more
prevalent forms of neurodegenerative disease, there is an escalat-
ing realization for its use as a viable target for new therapeutic
design. Instrumental work carried out on therapeutic design in
the body’s periphery (Higgs et al., 2012; Zhou et al., 2012) has
increasingly been implemented to investigate their value at restor-
ing iron homeostasis within the brain (Zecca et al., 2004; Badrick
and Jones, 2011; Zorzi et al., 2012). However, a signiﬁcant hurdle
in the use of these drugs has been the relative impermeability to
the blood brain barrier for some of the more effective peripheral
tissue therapeutics and the necessity to target iron in brain rather
than the periphery. This barrier is required to isolate and protect
the brain from the peripheral circulatory system and transport of
drugs across must either occur via active transport using recep-
tors or small lipid soluble molecules that can diffuse across the
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cellular plasma membrane [for review see (Zheng and Monnot,
2012)].
Iron selective chelators such as desferrioxamine have had lim-
ited success in the brain when administered peripherally, largely
due to their size and impermeability of the blood brain barrier
(Richardson, 2004). However, a number of smaller molecular
compounds with varying afﬁnity for iron such as deferiprone,
deferasirox, and clioquinol as well as their derivatives, have had
promising outcomes in preclinical trials on models of neurode-
generative disease (Kaur et al., 2003; Atamna and Frey, 2004;
Molina-Holgado et al., 2008; Rival et al., 2009; Prasanthi et al.,
2012). Recently there have been a series of reviews comprehen-
sively discussing preclinical studies on metal afﬁnity compounds
[for example Duce and Bush (2010), Ward et al. (2012), Weinreb
et al. (2013)]. Deferiprone has already been clinically approved
for the peripheral iron overload disorder thalassemia, and used
in other neurodegenerative diseases such as Friedreich’s ataxia
(Boddaert et al., 2007). A recent pilot clinical trial to test for
safety and efﬁcacy indicated 6-months deferiprone treatment of
early stage PD patients decreased motor handicap progression
(as measured by Uniﬁed PD Rating Scale) as well as SN iron
deposition (as measured by R2∗MRI; Devos et al., 2014) and a fur-
ther trial is currently underway (Clinical trial #’s NCT01539837).
Similarly, clinical trials in AD patients using a clioquinol deriva-
tive called PBT2 that has weaker afﬁnity for iron than other
translational metals such as copper and zinc, reduced Aβ in
CSF as well as improved executive cognitive function (Lan-
nfelt et al., 2008) and is currently in a further clinical trial
on AD and HD patients (Clinical trial #’s NCT00471211 and
NCT01590888).
While metal afﬁnity compounds have been the focus of most
iron therapeutic research in the past decade (Duce and Bush,
2010; Badrick and Jones, 2011; Roberts et al., 2012; Zorzi et al.,
2012), it is evident that care must be taken so as to prevent exces-
sive binding which could result in removal of too much iron
from the neuronal environment as the reduction in levels below
that required for normal physiological maintenance could be just
as detrimental to survival (as indicated in anemia). Inaccurate
administrative dose of a chelator may therefore only compound
the disease phenotype in which they are being used to ease or alter
the disease phenotype toward an iron deﬁciency-like pathology
that is just as harmful to the patient. Upon better understand-
ing of the brain’s capacity in regulating iron homeostasis both
within and between cell types perhaps an alternative approach
in the future may be to utilize the brain’s own iron homeostatic
system to restore the balance of iron. In so doing, recompart-
mentalizing iron to areas within the brain that have a better
capability to cope with oxidative stress-induced by redox-active
iron may go a long way toward alleviating the common underly-
ing defects that occur in these more prevalent neurodegenerative
diseases.
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